Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.

导出 OA

翻译打印收藏纠错

第一作者： Line H,Dohn

第一单位： Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

作者： Line H,Dohn ^[1] ; Peter,Thind ^[2] ; Lisbeth,Salling ^[3] ; Henriette,Lindberg ^[3] ; Sofie,Oersted ^[4] ; Ib J,Christensen ^[1] ; Ole D,Laerum ^[2] ; Martin,Illemann ^[5] ; Hans,von der Maase ^[6] ; Gunilla,Høyer-Hansen ^[2] ; Helle,Pappot ^[5]

作者单位： Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. ^[1] The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloes Vej 5, Building 3, 3rd Floor, 2200 Copenhagen, Denmark. ^[2] Department of Urology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. ^[3] Department of Oncology, Herlev and Gentofte Hospital, Herlev, Borgmester Ib Juuls Vej 1, 2730 Herlev, Denmark. ^[4] Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole Maaloes Vej 5, 2200 Copenhagen, Denmark. ^[5] Department of Surgical Gastroenterology, Hvidovre Hospital, 2650 Hvidovre, Denmark. ^[6]

关键词 biomarker bladder cancer blood plasma plasminogen activation recurrence survival uPAR urokinase receptor urothelial cancer

DOI 10.3390/cancers13102377

PMID 34069121

发布时间 2021-06-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交